识别骨髓增生异常综合征和急性髓系白血病中的骨髓微环境群体
2023年11月10日
2.2K 次观看
本文介绍了从骨髓增生异常综合征和急性髓系白血病的小鼠模型中分离和表征骨髓微环境群体的详细方案。该技术可识别非造血骨髓生态位（包括内皮细胞和间充质基质细胞）随疾病进展的变化。
我们的研究旨在探索骨髓不断变化的环境如何影响肿瘤的生长。我们开发了一种流式细胞术方案来分析骨髓和骨组织中的非免疫细胞，重点关注小鼠血液系统恶性肿瘤。该方法适用于研究各种小鼠模型中的骨髓。
我们的研究重点是分离和识别癌症进展过程中骨髓基质群的改变。了解它们对疾病发生和进展的影响可以为针对骨髓基质细胞中这些促进癌症变化的新疗法铺平道路。我们的方案独特地结合了机械和酶消化、磁耗竭和流式细胞术来描述骨髓微环境细胞组成。
它通过采用磁分离并结合来自骨骼和骨髓的细胞而脱颖而出，从而更全面地代表了这种微环境。
查看完整文字稿并访问数千部科学视频
概述
本文介绍了一种详细的协议，用于在骨髓增生异常综合征和急性髓系白血病的小鼠模型中分离和表征骨髓微环境群体。该研究重点分析骨髓中的非免疫细胞及其在癌症进展过程中的变化。
关键研究组成部分
科学领域
- 神经科学
- 血液学
- 癌症生物学
背景
- 骨髓微环境在肿瘤生长中起着至关重要的作用。
- 包括基质群体在内的非造血细胞在癌症进展过程中受到影响。
- 理解这些变化可以导致新的治疗策略。
- 该研究利用小鼠模型来模拟人类血液学恶性肿瘤。
研究目的
- 分离并识别骨髓基质群体的变化。
- 了解骨髓环境对疾病发作和进展的影响。
- 开发一个适用于各种模型的流式细胞术协议。
使用的方法
- 流式细胞术用于分析非免疫细胞。
- 机械和酶消化的组合。
- 磁性消除技术。
- 骨髓微环境细胞构成的表征。
主要结果
- 识别了癌症进展过程中骨髓基质群体的变化。
- 对骨髓小环境在肿瘤生长中的作用有了新的见解。
- 建立了一个适用于未来研究的稳健协议。
- 对靶向癌症治疗的潜在影响。
结论
- 骨髓微环境显著影响血液学恶性肿瘤。
- 理解基质变化对开发新的治疗方法至关重要。
- 该协议可以应用于各种癌症模型进行进一步研究。
常见问题
这项研究的主要焦点是什么？
该研究重点是在血液学恶性肿瘤的小鼠模型中分离和表征骨髓基质群体。
骨髓环境如何影响肿瘤生长？
骨髓微环境的变化可能通过改变基质细胞群体来促进肿瘤生长。
这项研究使用了什么方法？
该研究采用了流式细胞术、机械和酶消化以及磁性消除技术。
为什么这项研究很重要？
理解骨髓小环境在癌症中的作用可以导致新的治疗策略。
这个协议可以适用于其他模型吗？
是的，流式细胞术协议可以适用于研究各种小鼠模型。
Executive Industry Relevance
Dissecting the bone marrow microenvironment in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) addresses a critical challenge in understanding disease initiation and progression. High-resolution phenotyping of stromal and endothelial populations enables mechanistic de-risking and informs target validation for therapies aimed at the tumor-supportive niche. This capability strengthens predictive confidence at the discovery-to-preclinical inflection point for hematological malignancy portfolios.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of stromal and endothelial cell contributions to malignant transformation.
- Supports functional target validation by mapping niche alterations associated with disease states.
- Facilitates mechanistic de-risking of candidate targets within the bone marrow microenvironment.
- Provides a platform for hypothesis-driven exploration of tumor-microenvironment interactions.
Screening & Assay Development
- Prepares validated, phenotypically defined cell populations for downstream functional assays.
- Standardizes isolation and characterization workflows for reproducible quantitative outputs.
- Enables scalable flow cytometry-based screening of niche-modulating compounds.
- Supports reliable evaluation of candidate interventions targeting stromal or endothelial compartments.
Translational & Preclinical Research
- Aligns preclinical models with disease-relevant microenvironmental changes observed in MDS and AML.
- Enables continuity from discovery through preclinical validation of niche-targeted strategies.
- Supports risk-adjusted advancement of therapies modulating the tumor-supportive stroma.
- Provides mechanistic insights for translational biomarker development in hematological malignancies.
Pipeline & Workflow Integration
This protocol integrates into the discovery-to-preclinical continuum by enabling high-fidelity isolation and analysis of bone marrow niche populations in murine models of MDS and AML.
- Discovery Biology: Supports hypothesis testing on the role of stromal and endothelial cells in disease progression.
- Screening: Delivers reproducible, quantitative phenotyping for assay development and compound evaluation.
- Analytics: Provides flow cytometry-based readouts for comparative analysis of microenvironmental alterations.
- Translational Research: Bridges discovery findings to preclinical validation in disease-relevant systems.
- Enterprise Reuse: Offers a standardized, adaptable workflow for diverse hematological malignancy models.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target selection.
- Operational Value: Enhances standardization, reproducibility, and scalability of niche cell isolation and analysis.
- Strategic Value: Improves go/no-go decisions and capital efficiency by clarifying microenvironmental drivers of disease.
- Portfolio Impact: Enables risk-adjusted prioritization of niche-targeted therapeutic programs.
Implementation Considerations
- Requires expertise in flow cytometry, cell isolation, and murine model handling.
- Demands access to multicolor flow cytometry and magnetic separation infrastructure.
- Necessitates cross-team standardization of gating and phenotyping strategies.
- Adaptable to various murine models but may require optimization for specific disease contexts.
- Throughput and cell yield may be limited by tissue availability and technical complexity.
Biopharma FAQs
Why does null hypothesis testing matter for stromal population shifts?
Null hypothesis testing enables objective assessment of whether observed changes in stromal or endothelial populations are statistically significant, supporting robust target validation in the context of MDS and AML models.
How does independent variable isolation fit the bone marrow phenotyping workflow?
Isolating specific cell populations using magnetic depletion and flow cytometry allows precise attribution of microenvironmental changes to disease state or experimental intervention, strengthening mechanistic insights.
What do quantitative flow cytometry measurements enable in this protocol?
Quantitative flow cytometry provides reproducible enumeration and phenotyping of niche populations, enabling comparative analysis across disease models and experimental conditions.
Why are replication requirements critical for cross-functional collaboration?
Replication ensures that observed microenvironmental alterations are robust and reproducible, facilitating data integration and decision-making across discovery, screening, and translational teams.
What statistical analysis capabilities are required before implementing stromal phenotyping?
Teams must be equipped to perform statistical comparisons of cell population frequencies and validate significance thresholds to support actionable conclusions in R&D workflows.
